Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biological and Clinical Efficacy of Recombinant Zoster Vaccine (Shingrix) in Patients With Chronic Lymphocytic Leukemia

NCT06364033 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT06364033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06364033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biological and Clinical Efficacy of Recombinant Zoster Vaccine (Shingrix) in Patients With Chronic Lymphocytic Leukemia
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 31, 2024
Completion date
October 31, 2028
Enrollment
312 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, cll-like mbl, small lymphocytic lymphoma, varicella-zoster virus reactivation